[A case of gastric cancer with multiple liver metastases resistant to TS-1 responding to chemotherapy with paclitaxel plus doxifluridine]

Gan To Kagaku Ryoho. 2006 Apr;33(4):513-5.
[Article in Japanese]

Abstract

A 74-year-old man was revealed to have type 3 gastric cancer with synchronous multiple liver metastases. Despite treatment with TS-1 (120 mg/body), an increase in tumor size was demonstrated by computer tomography and endoscopy. We tried a course of a combination chemotherapy consisting of paclitaxel (PTX) plus doxifluridine (5'-DFUR ) to reduce the tumor. 5'-DFUR (600 mg/m(2)) was administered day 1 to 14 followed by 7 days'rest as one course. PTX (80 mg/m(2)) was infused on days 1 and 8. After 5 courses, the tumor markers decreased markedly, and computer tomography and endoscopy revealed remarkable tumor reduction which was thought to show a partial response. After 13 courses we discontinued this chemotherapy, so increase of the tumor marker was remarkable. This case suggests that PTX/5'-DFUR protocol is effective for clinical management of gastric cancer resistant to TS-1.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Drug Administration Schedule
  • Drug Combinations
  • Drug Resistance, Neoplasm*
  • Floxuridine / administration & dosage
  • Humans
  • Irinotecan
  • Liver Neoplasms / secondary*
  • Male
  • Oxonic Acid / pharmacology*
  • Paclitaxel / administration & dosage
  • Pyridines / pharmacology*
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology
  • Tegafur / pharmacology*

Substances

  • Drug Combinations
  • Pyridines
  • Floxuridine
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • Irinotecan
  • Paclitaxel
  • doxifluridine
  • Camptothecin